Clinical Trials Logo

Filter by:
NCT ID: NCT02813694 Completed - Clinical trials for Community Acquired Pneumonia

Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia

LEAP2
Start date: August 2016
Phase: Phase 3
Study type: Interventional

This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate community-acquired bacterial pneumonia

NCT ID: NCT02810457 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer

AVANA
Start date: September 7, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer

NCT ID: NCT02809183 Completed - Acidosis Clinical Trials

Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis

Start date: March 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This was a double-blind, placebo-controlled, parallel-design, 6-arm, fixed dose study. The study enrolled 135 adult male and female subjects with Stage 3 or 4 chronic kidney disease and low serum bicarbonate levels. The study was conducted in two parts. In Part 1 study drug dosing (TRC101 or placebo) continued for 14 days twice daily (BID). In Part 2 study drug dosing (TRC101 or placebo) continued for 14 days once daily (QD). The maximum study duration per subject was anticipated to be up to 42 days.

NCT ID: NCT02808819 Completed - Asthma Clinical Trials

A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist

MELTEMI
Start date: June 30, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to continue to characterize the safety profile of benralizumab administration and monitor the pharmacodynamic activity of the drug in those asthma patients who remain on treatment for at least 16 weeks and not more than 40 weeks in the predecessor study D3250C00021 (BORA, NCT02258542).

NCT ID: NCT02805439 Completed - Clinical trials for Major Depressive Disorder

Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant Treatment

Start date: March 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of S47445 versus placebo as adjunctive treatment of Major Depressive Disorder in patients with an inadequate response to antidepressant therapy.

NCT ID: NCT02804763 Completed - Clinical trials for Systemic Lupus Erythematosus (SLE)

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

Start date: June 2, 2016
Phase: Phase 2
Study type: Interventional

The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic Lupus Erythematosus.

NCT ID: NCT02799602 Completed - Clinical trials for Metastatic Hormone-sensitive Prostate Cancer

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

ARASENS
Start date: November 30, 2016
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive prostate cancer.

NCT ID: NCT02798471 Completed - Pulmonary Embolism Clinical Trials

Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

Start date: March 27, 2017
Phase: Phase 3
Study type: Interventional

This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE. This study is designed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban and to compare the efficacy and safety of edoxaban against standard of care in pediatric subjects with confirmed VTE.

NCT ID: NCT02796677 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

AMPLIFY - D6571C00001 Duaklir USA Phase III Study

Start date: July 5, 2016
Phase: Phase 3
Study type: Interventional

This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400μg/Formoterol Fumarate (AB/FF) 12 μg compared to individual components and TIO (Tiotropium) 18 μg when administered to patients with stable chronic obstructive pulmonary disease (COPD).

NCT ID: NCT02794285 Completed - Clinical trials for Active Systemic Lupus Erythematosus

Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

TULIP SLE LTE
Start date: June 30, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to characterise long-term safety and tolerability of intravenous anifrolumab.